Table 2.

Antiviral effects of L-BHDU and valyl-L-BHDU in SCID-Hu mice

Treatment	Dose (mg/kg/day)	ABWDa,b (±SD)	Mortality	Ave. VZV Growth Rateb,c (± SD)c
Vehicle 0.4% CMC	0	−1.0 (1.3)	2/21	0.43 (0.10)
ACV	120	−1.2 (0.9)	0/11	0.38 (0.07)
VACV	120	−2.9 (1.2)*	0/11	0.40 (0.09)
	200	−3.6 (1.5)*	0/10	0.27 (0.07) *
L-BHDU (1)	8	−2.9 (3.0)	1/5	0.33 (0.03)
	15	−4.3 (1.9)*	0/5	0.25 (0.09) *
	150	−1.5 (0.6)	0/5	0.22 (0.06) *
Valyl-L-BHDU (2)	10	−0.9 (0.8)	0/10	0.34 (0.14)
	30	−0.9 (2.1)	2/10	0.26 (0.07) *

^aAverage Body Weight Difference from Days 0–7 in grams

^bSD, standard deviation. One-way ANOVA and post hoc Dunnett’s Multiple Comparison Test.

^*= p<0.0001 compared to vehicle group

^cVZV growth rate [Log₁₀(photons/s/day)]